Prescription medicine
Moexipril First approved as Univasc
Moexipril (Univasc) is a prescription medicine with an FDA approval on record since 1995. FDA's NDC Directory lists it from 3 generic labelers, and pharmacies paid $1.00 per moexipril HCl 15 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- Boxed warning
Check it at the source: the moexipril FDA label on DailyMed (effective January 23, 2026, Glenmark Pharmaceuticals Inc., USA); the NDA 20312 record on Drugs@FDA; every moexipril label on DailyMed.
Highlights of the record
FDA label of January 23, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
FETAL TOXICITY •.
When pregnancy is detected, discontinue moexipril hydrochloride as soon as possible.
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See WARNINGS: Fetal Toxicity.
Used for
From the label: indications and usageMoexipril hydrochloride tablets are indicated for treatment of patients with hypertension.
Forms and strengths
- 7.5 mg
- 15 mg
Film-coated tablet.
On the market
- Earliest approval on file
- April 19, 1995 Univasc, Ucb Inc; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 4 first May 8, 2003; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 3 of which 3 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $1.00 per tablet Moexipril HCl 15 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2012 0 Class I among all firms' recalls; latest October 3, 2012
- FAERS reports
- 67 through July 30, 2026
What is moexipril used for?
From the label: indications and usageMoexipril hydrochloride tablets are indicated for treatment of patients with hypertension. They may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride tablets, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride tablets do not have a similar risk (see WARNINGS ). […]
FDA pharmacologic class: Angiotensin Converting Enzyme Inhibitor.
Source: FDA drug label (Moexipril Hydrochloride), Glenmark Pharmaceuticals Inc., USA, effective January 23, 2026 (SPL set baac91ad-f8ee-4694-89f8-5c47a8eda39a), via openFDA; the full label on DailyMed
Is there a generic for moexipril (Univasc)?
The FDA approved the first generic moexipril on May 8, 2003. 4 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists moexipril from 3 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1995 earliest approval on file
- 2003 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for moexipril (Univasc)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $1.00 per Moexipril HCl 15 mg tablet, up 2% from $0.979 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Moexipril HCl 7.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Moexipril HCl 15 mg tablet | Generic | $1.00 per tablet | $30.01 | +2% |
| Moexipril HCl 7.5 mg tablet | Generic | $0.897 per tablet | $26.91 | -6% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has moexipril been recalled?
The FDA's Enforcement Report lists 1 recall naming moexipril since 2012: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| October 3, 2012 | Class II | Paddock Laboratories, LLC | Paddock Laboratories, LLC are recalling one lot (2012028142) of Moexipril HCl Tablets 7.5mg (expiration 1/2014) because of a non-conformity dissolution failure … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the moexipril label say about other medicines?
The moexipril label names 11 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aliskiren | contraindications | Do not co-administer aliskiren with moexipril hydrochloride in patients with diabetes (see PRECAUTIONS, Drug Interactions ). |
| Amiloride | drug interactions | Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. |
| Captopril | warnings | Neutropenia/Agranulocytosis Another ACE inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in patients with uncomplicated hypertension, but more frequently in hypertensive patients with renal impairment, especially if they also have a collagen-vascular disease such as … |
| Cimetidine | drug interactions | Other Agents: No clinically important pharmacokinetic interactions occurred when moexipril hydrochloride was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. |
| Digoxin | drug interactions | Other Agents: No clinically important pharmacokinetic interactions occurred when moexipril hydrochloride was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. |
| Epinephrine | warnings | Appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) and/or measures to ensure a patent airway, should be promptly provided (see ADVERSE REACTIONS ). |
| Hydrochlorothiazide | drug interactions | Other Agents: No clinically important pharmacokinetic interactions occurred when moexipril hydrochloride was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. |
| Lithium | drug interactions | Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. |
| Spironolactone | drug interactions | Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. |
| Triamterene | drug interactions | Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. |
| Warfarin | drug interactions | Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. |
Source: FDA drug label (Moexipril Hydrochloride), Glenmark Pharmaceuticals Inc., USA, effective January 23, 2026 (SPL set baac91ad-f8ee-4694-89f8-5c47a8eda39a), via openFDA; the full label on DailyMed
What do FAERS reports show for moexipril?
The FDA Adverse Event Reporting System holds 67 reports that list moexipril among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 6 are coded as a death and 21 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other ACE inhibitors
- the pharmacologic class, with prices and generics
- Moexipril side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other